(VVUS) |
| 0 (0%) 04-16 06:26 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 32.52 |
| Resistance 1: | 27.84 |
| Pivot price: | 26.32 |
| Support 1: | 26.09 |
| Support 2: | 25.02 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Mon, 26 Sep 2022
Vertex Ventures US Raises $200 Million Third Fund to Double-down on high-conviction approach to venture capital - Business Wire
Mon, 03 Feb 2020
VVUS: ZenPep Deal Demonstrates PERT Interest - Zacks Small Cap Research
Fri, 18 May 2018
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs - InvestorPlace
Wed, 23 Mar 2016
Eisai slashes Belviq sales force as Arena marketing deal goes sour - Fierce Pharma
Fri, 11 Oct 2013
Auxilium Pharmaceuticals, Inc. Announces License Agreement For The Marketing Rights To STENDRA™ In The United States And Canada - PR Newswire
Wed, 10 Jul 2013
Drug Deal Can Only Help VIVUS, Inc. (VVUS) So Much - Insider Monkey
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
